---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-032436"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2022-11-15T23:59:59+00:00"
generated_at: "2026-06-21T18:01:07.241827+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Elite Pharmaceuticals Q2 FY2023: Revenue $16.3M (+4% YoY), Net Income $1.82M

## Summary
- Consolidated six-month revenue $16.3M, up 4% YoY vs prior year.
- Operating profit $2.1M; net income $1.82M for the six-month period.
- Revenue growth attributed to generic immediate-release and extended-release Adderall.
- Conference call on Nov 15, 2022 at 11:30 AM EST; dial-in 1-800-346-7359.

## SEC filing metadata
- accession: 0001493152-22-032436
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2022-11-15T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315222032436/0001493152-22-032436-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315222032436/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-032436
- JSON: https://secwatch.observer/filing/0001493152-22-032436.json
- Plain text: https://secwatch.observer/filing/0001493152-22-032436.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.